

Form PTO-1449 (modified)



APR 28 2006

Atty. Docket No.  
CLFR:114USSerial No.  
08/844,731**List of Patents and Publications for Applicant's Office****INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicant  
Staley A. BrodFiling Date:  
April 21, 1997Group:  
1761**U.S. Patent Documents**

See Page 1

**Foreign Patent Documents**

See Page 1

**Other Art**

See Page 1

**U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1						

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1						

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
/JS/	C1	Brod, "Ingested IFN-alpha: Results of a pilot study in relapsing-remitting MS," <i>Neurology</i> , 57:845-852, 2001.
/JS/	C2	Cummins <i>et al.</i> , "Oral use of human alpha interferon in cats," <i>J. Biol. Response Mod.</i> 7:513-423. 1988. (abstract)
/JS/	C3	Koren and Fleischmann, "Orally administered interferons suppress bone marrow function," <i>P.S.E.B.M.</i> , 204:155-164, 1993.
/JS/	C4	Soos <i>et al.</i> , "Cutting Edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate," <i>J. Immunol.</i> , 169: 2231-2235, 2002.

25646123.1

EXAMINER: /Jegatheesan Seharaseyon/ DATE CONSIDERED: 05/24/2007

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.